Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 28;11(5):1149.
doi: 10.3390/microorganisms11051149.

Invasive Candida parapsilosis Bloodstream Infections in Children: The Antifungal Susceptibility, Clinical Characteristics and Impacts on Outcomes

Yao-Sheng Wang  1   2 , Jen-Fu Hsu  1   3 , Wei-Ju Lee  1   2 , Shao-Hung Wang  4 , Shih-Ming Chu  1   3 , Hsuan-Rong Huang  1   3 , Peng-Hong Yang  1   3 , Ren-Huei Fu  1   3 , Ming-Horng Tsai  1   5
Affiliations

Invasive Candida parapsilosis Bloodstream Infections in Children: The Antifungal Susceptibility, Clinical Characteristics and Impacts on Outcomes

Yao-Sheng Wang et al. Microorganisms. .

Abstract

Background: Candida parapsilosis is the most common non-albicans candida species that causes invasive candidiasis, but little is known about its impacts on the outcomes of pediatric patients. We aimed to characterize the clinical characteristics, risk factors and outcomes of C. parapsilosis bloodstream infections (BSIs) in children. Methods: All pediatric patients with Candida parapsilosis BSIs between 2005 and 2020 from a medical center in Taiwan were enrolled and analyzed. The antifungal susceptibility, clinical manifestations, management and outcomes were investigated. Cases of Candida parapsilosis BSIs were compared between patients with C. albicans BSIs and other Candida spp. BSIs. Results: During the study period, 95 episodes (26.0% of total cases) of Candida parapsilosis BSIs were identified and analyzed. No significant difference was found between pediatric patients with C. parapsilosis BSIs and those with C. albicans BSIs in terms of patients' demographics, most chronic comorbidities or risk factors. Pediatric patients with C. parapsilosis BSIs were significantly more likely to have previous azole exposure and be on total parenteral nutrition than those with C. albicans BSIs (17.9 vs. 7.6% and 76.8 vs. 63.7%, p = 0.015 and 0.029, respectively). The duration of C. parapsilosis candidemia was relatively longer, and therefore patients often required a longer duration of antifungal treatment when compared with those of C. albicans candidemia, although the candidemia-attributable mortality rates were comparable. Of the C. parapsilosis isolates, 93.7% were susceptible to all antifungal agents, and delayed appropriate antifungal treatment was an independent factor in treatment failure. Conclusions: Pediatric patients with C. parapsilosis BSIs were more likely to have previous azole exposure and be on total parenteral nutrition, and the clinical significances included a longer duration of candidemia and patients often required a longer duration of antifungal treatment.

Keywords: Candida parapsilosis; bloodstream infection; candidemia; intensive care unit; mortality.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interest.

Figures

Figure 1
Figure 1
The case distributions of different Candida species that caused pediatric Candida bloodstream infections (BSIs) in the study period, 2005–2020, in Chang Gung Memorial Hospital.
See this image and copyright information in PMC

References

    1. Zheng Y.-J., Xie T., Wu L., Liu X.-Y., Zhu L., Chen Y., Mao E.-Q., Han L.-Z., Chen E.-Z., Yang Z.-T. Epidemiology, species distribution, and outcome of nosocomial Candida spp. bloodstream infection in Shanghai: An 11-year retrospective analysis in a tertiary care hospital. Ann. Clin. Microbiol. Antimicrob. 2021;20:34. doi: 10.1186/s12941-021-00441-y. - DOI - PMC - PubMed
    1. Lee W.-J., Hsu J.-F., Chen Y.-N., Wang S.-H., Chu S.-M., Huang H.-R., Yang P.-H., Fu R.-H., Tsai M.-H. Pediatric Candida Bloodstream Infections Complicated with Mixed and Subsequent Bacteremia: The Clinical Characteristics and Impacts on Outcomes. J. Fungi. 2022;8:1155. doi: 10.3390/jof8111155. - DOI - PMC - PubMed
    1. Montravers P., Perrigault P., Timsit J., Mira J., Lortholary O., Leroy O., Gangneux J., Guillemot D., Bensoussan C., Bailly S., et al. Antifungal therapy for patients with proven or suspected Candida peritonitis: Amarcand2, a prospective cohort study in French intensive care units. Clin. Microbiol. Infect. 2016;23:117.e1–117.e8. doi: 10.1016/j.cmi.2016.10.001. - DOI - PubMed
    1. Piqueras A., Ganapathi L., Carpenter J.F., Rubio T., Sandora T.J., Flett K.B., Köhler J.R. Trends in Pediatric Candidemia: Epidemiology, Anti-Fungal Susceptibility, and Patient Characteristics in a Children’s Hospital. J. Fungi. 2021;7:78. doi: 10.3390/jof7020078. - DOI - PMC - PubMed
    1. Silvester E.J., Watanabe M.M.Y., Pittet L.F., Boast A., Bryant P.A., Haeusler G.M., Daley A.J., Curtis N., Gwee A. Candidemia in Children: A 16-year Longitudinal Epidemiologic Study. Pediatr. Infect. Dis. J. 2021;40:537–543. doi: 10.1097/INF.0000000000003082. - DOI - PubMed

LinkOut - more resources